Opus Genetics Reports $49.6 Million Net Loss and $14.2 Million Revenue for Fiscal Year 2025

Opus Genetics, Inc., a clinical-stage biopharmaceutical company focused on developing gene therapies for inherited retinal diseases (IRDs), reported a net loss of $49.6 million for the fiscal year ending December 31, 2025, a decrease from a loss of $57.5 million in the previous year. The company generated $14.2 million in license and collaboration revenue, primarily from its partnership with Viatris, compared to $11.0 million in 2024. This increase in revenue reflects the successful commercialization of RYZUMVI®, an FDA-approved treatment for pharmacologically induced mydriasis, which was launched in April 2024.

Opus Genetics has made significant strides in its clinical pipeline, particularly with its lead gene therapy candidates, OPGx-LCA5 and OPGx-BEST1. The company is currently conducting a Phase 1/2 clinical trial for OPGx-LCA5, which has shown promising results in improving vision in participants. The FDA has granted this program several designations, including Rare Pediatric Disease and Regenerative Medicine Advanced Therapy (RMAT). The company plans to initiate a Phase 3 trial for OPGx-LCA5 in the second half of 2026, with topline data expected approximately one year later. Similarly, the OPGx-BEST1 program has received FDA clearance to begin clinical trials, with initial data anticipated in mid-2026.

Operationally, Opus Genetics has expanded its workforce to 27 full-time employees, focusing on clinical research, development, and regulatory activities. The company has also entered into various strategic partnerships, including a collaboration with the Foundation Fighting Blindness to support its gene therapy programs. However, the company faces challenges in establishing its own sales and marketing infrastructure, as it currently relies on Viatris for the commercialization of RYZUMVI® and other products.

Looking ahead, Opus Genetics anticipates continued increases in research and development expenses as it advances its clinical trials and seeks regulatory approvals for its product candidates. The company has sufficient cash reserves of $45.1 million as of December 31, 2025, bolstered by recent financing activities, including a $25 million private placement in February 2026. Despite these resources, the company acknowledges the need for additional capital to support its ongoing operations and product development efforts, emphasizing the inherent risks associated with clinical trials and regulatory approvals in the biopharmaceutical industry.